Semaglutide for Diabetes: What the Evidence Shows
What human and animal studies show about Semaglutide for diabetes, how strong that evidence is, and what is still unproven.
- Strongest evidence
- Human RCT
- Human studies
- 1,986
- PubMed records, our ledger
- Animal studies
- 139
- PubMed records, our ledger
- Studies we summarised
- 5
- with an outcome for diabetes
Evidence for diabetes
Each row is an outcome related to diabetes from a published study, strongest design first. Animal and cell results are labelled and are not human results. User reports are not counted as evidence here.
| Outcome | Result | Study type | Source |
|---|---|---|---|
| Major kidney disease events | The risk of the primary kidney composite was 24% lower with semaglutide (331 vs 410 first events; hazard ratio 0.76). | Human RCTn = 3533 | The New England journal of medicine 2024, PMID 38785209 |
| Body weight change | Mean bodyweight changed by -9·6% with semaglutide 2·4 mg vs -3·4% with placebo at week 68 in people with diabetes. | Human RCTn = 1210 | Lancet 2021, PMID 33667417 |
| Major adverse cardiovascular events | Major events occurred in 3.8% on oral semaglutide vs 4.8% on placebo (hazard ratio 0.79, 95% CI 0.57 to 1.11), establishing noninferiority. | Human RCTn = 3183 | The New England journal of medicine 2019, PMID 31185157 |
| Glycaemic control vs dulaglutide | Glycated hemoglobin fell by 1·5 points (semaglutide 0·5 mg) vs 1·1 (dulaglutide 0·75 mg), and by 1·8 (semaglutide 1·0 mg) vs 1·4 (dulaglutide 1·5 mg). | Human controlled trialn = 1201 | The lancet. Diabetes & endocrinology 2018, PMID 29397376 |
| Body weight vs dulaglutide | Bodyweight fell by 4·6 kg with semaglutide 0·5 mg vs 2·3 kg with dulaglutide 0·75 mg. | Human controlled trialn = 1201 | The lancet. Diabetes & endocrinology 2018, PMID 29397376 |
| Cardiovascular death, MI or stroke | The primary composite occurred in 6.6% on semaglutide vs 8.9% on placebo (hazard ratio 0.74, 95% CI 0.58 to 0.95). | Human RCTn = 3297 | The New England journal of medicine 2016, PMID 27633186 |
PubMed records for Semaglutide and diabetes: 1,986 human, 139 animal (search counts, not studies we reviewed). Grades follow our evidence scale.
How strong is it?
A human randomized trial outweighs any number of animal studies. Animal and cell results show a mechanism worth testing, not that it works in people.
Other peptides people research for diabetes
All peptides for diabetes, comparedCommon questions
Does Semaglutide help with diabetes?
The strongest study we summarise for diabetes is human rct evidence, across 5 studies with an outcome for diabetes. A trial result is not an approval; see the legal status.
Is Semaglutide approved for diabetes?
Semaglutide is FDA approved (Ozempic, Wegovy, Rybelsus). Which conditions that approval covers is set by the label; use for anything else is off-label.
What is the best peptide for diabetes?
There is no single answer. Our diabetes overview compares each candidate by evidence grade and legal status rather than by popularity.
More on Semaglutide
Sources
- 1Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.The New England journal of medicine · 2024PMID 38785209Accessed 2 Oct 2026
- 2Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.Lancet (London, England) · 2021PMID 33667417Accessed 2 Oct 2026
- 3Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.The New England journal of medicine · 2019PMID 31185157Accessed 2 Oct 2026
- 4Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.The lancet. Diabetes & endocrinology · 2018PMID 29397376Accessed 2 Oct 2026
- 5Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.The New England journal of medicine · 2016PMID 27633186Accessed 2 Oct 2026
Found an error? Report a correction.